Literature DB >> 30604631

Imaging in myeloma with focus on advanced imaging techniques.

Tara Barwick1,2, Laure Bretsztajn1, Kathryn Wallitt1, Dimitri Amiras1, Andrea Rockall1,2,3, Christina Messiou3,4.   

Abstract

In recent years, there have been major advances in the imaging of myeloma with whole body MRI incorporating diffusion-weighted imaging, emerging as the most sensitive modality. Imaging is now a key component in the work-up of patients with a suspected diagnosis of myeloma. The International Myeloma Working Group now specifies that more than one focal lesion on MRI or lytic lesion on whole body low-dose CT or fludeoxyglucose (FDG) PET/CT fulfil the criteria for bone damage requiring therapy. The recent National Institute for Health and Care Excellence myeloma guidelines recommend imaging in all patients with suspected myeloma. In addition, there is emerging data supporting the use of functional imaging techniques (WB-DW MRI and FDG PET/CT) to predict outcome and evaluate response to therapy. This review summarises the imaging modalities used in myeloma, the latest guidelines relevant to imaging and future directions.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30604631      PMCID: PMC6540859          DOI: 10.1259/bjr.20180768

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  63 in total

1.  Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma.

Authors:  Patric Kröpil; Roland Fenk; Lars B Fritz; Dirk Blondin; Guido Kobbe; Ulrich Mödder; Mathias Cohnen
Journal:  Eur Radiol       Date:  2007-10-09       Impact factor: 5.315

2.  Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.

Authors:  Marius Horger; Claus D Claussen; Ulrike Bross-Bach; Reinhard Vonthein; Tobias Trabold; Martin Heuschmid; Christina Pfannenberg
Journal:  Eur J Radiol       Date:  2005-05       Impact factor: 3.528

3.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Authors:  T L Chenevert; L D Stegman; J M Taylor; P L Robertson; H S Greenberg; A Rehemtulla; B D Ross
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

4.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

Authors:  Ronald Walker; Bart Barlogie; Jeffrey Haessler; Guido Tricot; Elias Anaissie; John D Shaughnessy; Joshua Epstein; Rudy van Hemert; Eren Erdem; Antje Hoering; John Crowley; Ernest Ferris; Klaus Hollmig; Frits van Rhee; Maurizio Zangari; Mauricio Pineda-Roman; Abid Mohiuddin; Shmuel Yaccoby; Jeffrey Sawyer; Edgardo J Angtuaco
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

5.  Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.

Authors:  Andrea Baur-Melnyk; Sonja Buhmann; Christoph Becker; Stefan Oswald Schoenberg; Nicola Lang; Reiner Bartl; Maximilian Ferdinand Reiser
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

6.  Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.

Authors:  Paul J Kim; Rodney J Hicks; Andrew Wirth; Gail Ryan; John F Seymour; H Miles Prince; Michael P Mac Manus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-27       Impact factor: 7.038

7.  18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.

Authors:  Cristina Nanni; Domenico Rubello; Elena Zamagni; Paolo Castellucci; Valentina Ambrosini; Giancarlo Montini; Michele Cavo; Filippo Lodi; Cinzia Pettinato; Gaia Grassetto; Roberto Franchi; Milton D Gross; Stefano Fanti
Journal:  In Vivo       Date:  2008 Jul-Aug       Impact factor: 2.155

8.  Positron emission tomography (PET) for staging of solitary plasmacytoma.

Authors:  Holger Schirrmeister; Andreas K Buck; Lothar Bergmann; Sven N Reske; Martin Bommer
Journal:  Cancer Biother Radiopharm       Date:  2003-10       Impact factor: 3.099

9.  Whole-Body MRI versus PET in assessment of multiple myeloma disease activity.

Authors:  Conor P Shortt; Tadhg G Gleeson; Karen A Breen; John McHugh; Martin J O'Connell; Peter J O'Gorman; Stephen J Eustace
Journal:  AJR Am J Roentgenol       Date:  2009-04       Impact factor: 3.959

10.  Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).

Authors:  T G Gleeson; J Moriarty; C P Shortt; J P Gleeson; P Fitzpatrick; B Byrne; J McHugh; M O'Connell; P O'Gorman; S J Eustace
Journal:  Skeletal Radiol       Date:  2008-11-14       Impact factor: 2.199

View more
  5 in total

1.  Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.

Authors:  Kaiwen Wang; Elsa Lee; Shedrack Kenis; Simon Hallam; Athar Haroon; Simon Wan; Neil Rabin; Antonio Rojas-Garcia; Anwar Padhani; Sola Adeleke
Journal:  Eur Radiol       Date:  2022-01-14       Impact factor: 7.034

2.  Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?

Authors:  Leo Rasche; Manoj Kumar; Grant Gershner; Rohan Samant; Rudy Van Hemert; Anke Heidemeier; Constantin Lapa; Thorsten Bley; Andreas Buck; James McDonald; Jens Hillengass; Joshua Epstein; Sharmilan Thanendrarajan; Carolina Schinke; Frits van Rhee; Maurizio Zangari; Bart Barlogie; Faith E Davies; Gareth J Morgan; Niels Weinhold
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

Review 3.  Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma.

Authors:  Mohammad Keilani; Franz Kainberger; Anna Pataraia; Timothy Hasenöhrl; Barbara Wagner; Stefano Palma; Fadime Cenik; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2019-07-02       Impact factor: 1.704

4.  18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?

Authors:  Romans Zukovs; Christina Antke; Eduards Mamlins; Lino Morris Sawicki; Annemarie Mohring; David Lopez Y Niedenhoff; Amelie Boquoi; Mustafa Kondakci; Gerald Antoch; Hans-Wilhelm Müller; Roland Fenk; Rainer Haas
Journal:  BMC Med Imaging       Date:  2022-04-04       Impact factor: 1.930

Review 5.  Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.

Authors:  Frederic E Lecouvet; Marie-Christiane Vekemans; Thomas Van Den Berghe; Koenraad Verstraete; Thomas Kirchgesner; Souad Acid; Jacques Malghem; Joris Wuts; Jens Hillengass; Vincent Vandecaveye; François Jamar; Olivier Gheysens; Bruno C Vande Berg
Journal:  Skeletal Radiol       Date:  2021-08-07       Impact factor: 2.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.